|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma.
|
16230378 |
2005 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Two correlated variants (r² = 0.99 in controls), rs11894252 (P = 1.8 × 10⁻⁸) and rs7579899 (P = 2.3 × 10⁻⁹), map to EPAS1 on 2p21, which encodes hypoxia-inducible-factor-2 alpha, a transcription factor previously implicated in RCC.
|
21131975 |
2011 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this issue of Cancer Discovery, Mathew and colleagues report that miR-30c-2-3p and miR-30a-3p downregulation in ccRCC promotes increased expression of HIF2α.
|
24402943 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To explore the HIF-1α, HIF-2α and c-Myc baseline expression as potential predictors of sunitinib outcome as well as the effectiveness and safety with sunitinib in patients with metastatic ccRCC in routine clinical practice.
|
29033582 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrate that functional delivery of a HIF2α-specific RNAi trigger resulted in HIF2α gene silencing and subsequent tumor growth inhibition and degeneration in an established orthotopic ccRCC xenograft model.<i></i>.
|
29079709 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In kidney cancer, HIF-2α is believed to be the most important driver for development and progression of clear cell renal cell carcinoma (ccRCC), highlighting the therapeutic potential of HIF-2 antagonists in this disease.
|
28217462 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The hypoxia-inducible factors HIF1α and HIF2α play a crucial role in ccRCC initiation and progression.
|
27507852 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HIF-1α, HIF-2α and CAIX were up-regulated in 88.2% (15/17), 100% (17/17) and 88.2% (15/17) of tumors respectively and their expression is independent of VHL status. hnRNP A2/B1 and osteopontin expression was variable in CCRCCs and had no association with VHL genetic status.
|
21547579 |
2011 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two recent independent studies published in <i>Nature</i> show robust responses of clear cell renal cell carcinoma (ccRCC) cell lines, preclinical ccRCC xenograft models and, remarkably, a patient with progressive ccRCC despite receiving multiple lines of treatment, to the long-awaited, recently developed inhibitors of hypoxia-inducible factor 2-alpha (HIF2α).
|
28667082 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
EPAS1 was detected in all of the RCC cell lines examined.
|
11301389 |
2001 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
|
20032376 |
2009 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
HIF2A germline-mutation-induced polycythemia in a patient with VHL-associated renal-cell carcinoma.
|
29172931 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings also suggest that MTHFD2 and HIF-2α form a positive feedforward loop in RCC, promoting metabolic reprograming and tumor growth.
|
31289360 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hypoxia-inducible factors, HIF-1α and HIF-2α, are expressed in the majority of ccRCC.
|
30144808 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrate that HIF2α promotes lipid storage, ER homeostasis, and cell viability in ccRCC via upregulation of the LD coat protein PLIN2, revealing a novel function for the well-documented "clear-cell" phenotype and identifying ER stress as a targetable vulnerability created by HIF2α/PLIN2 suppression in this common renal malignancy.
|
25829424 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).
|
30289716 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein, we provide mechanistic evidence that HIF-2α can be degraded in cytoplasm under hypoxic conditions via the 26S proteasome and that MDM2 is the E3 ligase which induces the hypoxic degradation of HIF-2α in PI-3K-dependent manner in VHL-deficient RCC cells.
|
25578041 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.
|
23378636 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These studies validate HIF2α as a therapeutic target in ccRCC, reveal variable sensitivity to HIF2α antagonism, and provide the foundation for predictive biomarker-driven clinical trials.
|
27728802 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hypoxia-inducible factor 2alpha (HIF-2α) antagonists -PT2385, and PT2399 have been shown to have promising results in the management of clear cell renal cell carcinoma by targeting the HIF-2α pathway in recent and ongoing clinical trials (PT2799).
|
28946040 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein, we summarize the molecular background behind the use of HIF-2α inhibitors in ccRCC and give an overview of the development of new agents in this setting.
|
28259286 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma.
|
26439684 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A small molecule inhibitor that binds to HIF-2α and blocks dimerization with HIF-1β is in clinical trials for the treatment of renal cell carcinoma.
|
30625281 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Taken together, the findings of this study suggest that the protein levels of HIF2A and VEGFA in tumor tissue may serve as independent prognostic factors in ccRCC. ccRCC patients with increased intratumoral HIF2A and VEGFA protein levels, and unaltered VHL protein levels, are not likely to benefit from sunitinib treatment following nephrectomy; however, this hypothesis requires verification by large‑scale replication studies.
|
31268155 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
|
28951458 |
2017 |